Engineered immune cells take on aggressive MS in early trial
NCT ID NCT07178431
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called MB-CART2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified to target and attack harmful immune cells driving MS. The goal is to see if it is safe and can stop disease activity, including relapses, worsening disability, and new brain lesions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité Universitätsmedizin Berlin
RECRUITINGBerlin, 13353, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?